open access

Vol 75, No 10 (2017)
Original articles
Published online: 2017-06-28
Submitted: 2017-01-06
Accepted: 2017-05-25
Get Citation

Increased plasma asymmetric dimethylarginine level is associated with ascending aorta dilatation: a case-control study

Muhammet Hulusi Satılmışoğlu, Vesile Örnek Diker, Ömer Taşbulak, Mustafa Diker, Ali Birand, Mehmet Kaya, Taner İyigün, Abdurrahman Eksik
DOI: 10.5603/KP.a2017.0123
·
Kardiol Pol 2017;75(10):1020-1026.

open access

Vol 75, No 10 (2017)
Original articles
Published online: 2017-06-28
Submitted: 2017-01-06
Accepted: 2017-05-25

Abstract

Background: Asymmetric dimethylarginine (ADMA) is an endogenous inhibitor of nitric oxide synthase.

Aim: We aimed to determine plasma ADMA levels in patients with ascending aorta dilatation in comparison to those without aorta dilatation, and to evaluate the diagnostic, predictive, and prognostic value of serum ADMA level for aorta dilatation.

Methods: This was a cross-sectional case-control study. A total of 104 consecutive patients (female/male, 35/69; mean age, 62.75 ± 13.11 years) diagnosed with ascending aorta dilatation (≥ 4.5 cm) on echocardiography (case group), and 52 age-and gender-matched patients (female/male, 17/35; mean age, 63.44 ± 7.56 years) with normal aorta dimensions (≤ 3.8 cm) (control group) were included. Routine biochemical and haematological analysis in addition to measurement of serum ADMA level were performed.

Results: The mean diameter of ascending aorta measured on echocardiography was 4.95 ± 0.57 cm and 3.34 ± 0.36 cm in patients with aorta dilatation and those without aorta dilatation, respectively (p < 0.001). Serum ADMA level was significantly higher in patients with aorta dilatation than in the control group (1.70 ± 1.12 μmol/L vs. 0.79 ± 0.76 μmol/L, respectively, p < 0.001). There was significant positive correlation between ADMA level and aortic diameter in Spearman correlation analysis (r = 0.317, p < 0.001). In linear regression analysis, ADMA was found to be a significant independent predictor of aorta diameter (Beta = 0.26, p < 0.001). Receiver-operator characteristic curve analysis also revealed that serum ADMA cut-off level over 0.29 μmol/L predicts aorta dilatation (≥ 4.5 cm) with 94% sensitivity and 92% specificity and with high ac­curacy (area under curve: 0.786; 95% confidence interval: 0.709–0.863, p < 0.001).

Conclusions: Serum ADMA level is diagnostic for ascending aorta dilatation with high sensitivity and specificity, and should be considered for use in clinical diagnosis of aorta dilatation.  

Abstract

Background: Asymmetric dimethylarginine (ADMA) is an endogenous inhibitor of nitric oxide synthase.

Aim: We aimed to determine plasma ADMA levels in patients with ascending aorta dilatation in comparison to those without aorta dilatation, and to evaluate the diagnostic, predictive, and prognostic value of serum ADMA level for aorta dilatation.

Methods: This was a cross-sectional case-control study. A total of 104 consecutive patients (female/male, 35/69; mean age, 62.75 ± 13.11 years) diagnosed with ascending aorta dilatation (≥ 4.5 cm) on echocardiography (case group), and 52 age-and gender-matched patients (female/male, 17/35; mean age, 63.44 ± 7.56 years) with normal aorta dimensions (≤ 3.8 cm) (control group) were included. Routine biochemical and haematological analysis in addition to measurement of serum ADMA level were performed.

Results: The mean diameter of ascending aorta measured on echocardiography was 4.95 ± 0.57 cm and 3.34 ± 0.36 cm in patients with aorta dilatation and those without aorta dilatation, respectively (p < 0.001). Serum ADMA level was significantly higher in patients with aorta dilatation than in the control group (1.70 ± 1.12 μmol/L vs. 0.79 ± 0.76 μmol/L, respectively, p < 0.001). There was significant positive correlation between ADMA level and aortic diameter in Spearman correlation analysis (r = 0.317, p < 0.001). In linear regression analysis, ADMA was found to be a significant independent predictor of aorta diameter (Beta = 0.26, p < 0.001). Receiver-operator characteristic curve analysis also revealed that serum ADMA cut-off level over 0.29 μmol/L predicts aorta dilatation (≥ 4.5 cm) with 94% sensitivity and 92% specificity and with high ac­curacy (area under curve: 0.786; 95% confidence interval: 0.709–0.863, p < 0.001).

Conclusions: Serum ADMA level is diagnostic for ascending aorta dilatation with high sensitivity and specificity, and should be considered for use in clinical diagnosis of aorta dilatation.  

Get Citation

Keywords

aorta dilatation, asymmetric dimethylarginine, biomarker, diagnosis

About this article
Title

Increased plasma asymmetric dimethylarginine level is associated with ascending aorta dilatation: a case-control study

Journal

Kardiologia Polska (Polish Heart Journal)

Issue

Vol 75, No 10 (2017)

Pages

1020-1026

Published online

2017-06-28

DOI

10.5603/KP.a2017.0123

Bibliographic record

Kardiol Pol 2017;75(10):1020-1026.

Keywords

aorta dilatation
asymmetric dimethylarginine
biomarker
diagnosis

Authors

Muhammet Hulusi Satılmışoğlu
Vesile Örnek Diker
Ömer Taşbulak
Mustafa Diker
Ali Birand
Mehmet Kaya
Taner İyigün
Abdurrahman Eksik

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By "Via Medica sp. z o.o." sp.k., Świętokrzyska 73 street, 80–180 Gdańsk, Poland

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail: viamedica@viamedica.pl